IRAK4 Inhibitor
Oncology
PreclinicalStatus Unknown
Key Facts
About Emmaus Life Sciences
Emmaus Life Sciences is a biopharmaceutical company with a mission to develop and commercialize innovative therapies, initially for rare diseases. Its primary achievement is the 2017 FDA approval of Endari (L-glutamine oral powder) for sickle cell disease, establishing a commercial foundation. The company's strategy involves expanding Endari's global footprint, exploring its glutamine-based science in new indications like diverticulosis, and developing a novel cell sheet engineering platform. Recent leadership changes and a focus on financial improvement signal a period of strategic transition.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |